Loading clinical trials...
Loading clinical trials...
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
Conditions
Interventions
LY4057996 SC
LY4057996 IV
+6 more
Locations
1
Germany
Profil Institut für Stoffwechselforschung
Neuss, Germany
Start Date
May 16, 2025
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2026
Last Updated
March 11, 2026
NCT06513026
NCT06807190
NCT04786262
NCT06748963
NCT06329375
NCT06959901
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions